

## Special Issue

# Ablation Treatment for Malignant Tumors

### Message from the Guest Editors

Image-guided ablation techniques have emerged as an increasingly important treatment modality for a wide range of malignant tumors. Radiofrequency ablation, microwave ablation, cryoablation, and other non-thermal techniques are now being integrated into multidisciplinary oncological care, offering minimally invasive alternatives or complementary options to surgery, systemic therapy, and radiotherapy. Advances in imaging guidance, ablation technology, and peri-procedural patient management have significantly improved safety, efficacy, and oncological outcomes. Moreover, ongoing research explores novel indications, combination strategies with immunotherapy, and the role of ablation in oligometastatic disease. This Special Issue aims to highlight recent progress, clinical applications, and future perspectives of ablation treatment for both primary and metastatic malignancies across different organ systems. We welcome original research, reviews, and technical reports that provide new insights into optimizing ablation strategies, patient selection, and long-term outcomes.

---

### Guest Editors

Dr. Madelon Dijkstra  
Prof. Dr. Martijn Meijerink  
Dr. Susan Van Der Lei

---

### Deadline for manuscript submissions

30 September 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/258909](https://mdpi.com/si/258909)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)